Tarsus Pharmaceuticals Files Prospectus Related To The Proposed Offer And Resale Of Up To 2.91M Shares Of Common Stock By Selling Stockholders
-SEC Filing
Stocks · News reference
Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tarsus Pharmaceuticals To Present 11 Abstracts On XDEMVY, Demodex Blepharitis, And Ocular Rosacea At American Academy Of Optometry Meeting
Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target
Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.